-DOCSTART- -X- O
Using -X- _ O
the -X- _ O
Taiwan -X- _ O
nationwide -X- _ O
laboratory-confirmed -X- _ O
severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
database -X- _ O
, -X- _ O
we -X- _ O
analyzed -X- _ O
neutralizing -X- _ O
antibody -X- _ O
in -X- _ O
relation -X- _ O
to -X- _ O
clinical -X- _ O
outcomes. -X- _ O
With -X- _ O
a -X- _ O
linear -X- _ O
mixed -X- _ O
model -X- _ O
, -X- _ O
neutralizing -X- _ B-Intervention
antibody -X- _ I-Intervention
titer -X- _ O
was -X- _ O
shown -X- _ O
to -X- _ O
peak -X- _ O
between -X- _ O
week -X- _ O
5 -X- _ O
and -X- _ O
week -X- _ O
8 -X- _ O
after -X- _ O
onset -X- _ O
and -X- _ O
to -X- _ O
decline -X- _ O
thereafter -X- _ O
, -X- _ O
with -X- _ O
a -X- _ O
half-life -X- _ O
of -X- _ O
6.4 -X- _ O
weeks. -X- _ O
Patients -X- _ O
with -X- _ O
a -X- _ O
longer -X- _ O
illness -X- _ O
showed -X- _ O
a -X- _ O
lower -X- _ O
neutralizing -X- _ B-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
than -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
shorter -X- _ I-Outcome
illness -X- _ I-Outcome
duration -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.008 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
When -X- _ I-Outcome
early -X- _ I-Outcome
responders -X- _ I-Outcome
were -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
most -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
who -X- _ I-Outcome
seroconverted -X- _ I-Outcome
on -X- _ I-Outcome
and -X- _ I-Outcome
after -X- _ I-Outcome
week -X- _ I-Outcome
3 -X- _ I-Outcome
of -X- _ I-Outcome
illness -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
small -X- _ I-Outcome
proportion -X- _ I-Outcome
( -X- _ I-Outcome
17.4 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
early -X- _ I-Outcome
responders -X- _ I-Outcome
( -X- _ I-Outcome
antibody -X- _ I-Outcome
detectable -X- _ I-Outcome
within -X- _ I-Outcome
2 -X- _ I-Outcome
weeks -X- _ I-Outcome
) -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
higher -X- _ I-Outcome
death -X- _ I-Outcome
rate -X- _ I-Outcome
( -X- _ I-Outcome
29.6 -X- _ I-Outcome
% -X- _ I-Outcome
vs. -X- _ I-Outcome
7.8 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
( -X- _ I-Outcome
Fisher -X- _ I-Outcome
exact -X- _ I-Outcome
test -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.004 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
shorter -X- _ I-Outcome
survival -X- _ I-Outcome
time -X- _ I-Outcome
of -X- _ I-Outcome
< -X- _ I-Outcome
2 -X- _ I-Outcome
weeks -X- _ I-Outcome
( -X- _ I-Outcome
Fisher -X- _ I-Outcome
exact -X- _ I-Outcome
test -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.013 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
were -X- _ I-Outcome
more -X- _ I-Outcome
likely -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
> -X- _ I-Outcome
60 -X- _ I-Outcome
years -X- _ I-Outcome
of -X- _ I-Outcome
age -X- _ I-Outcome
( -X- _ I-Outcome
Fisher -X- _ I-Outcome
exact -X- _ I-Outcome
test -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.01 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Our -X- _ O
findings -X- _ O
have -X- _ O
implications -X- _ O
for -X- _ O
understanding -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
SARS -X- _ O
and -X- _ O
for -X- _ O
SARS -X- _ O
vaccine -X- _ O
research -X- _ O
and -X- _ O
development -X- _ O
. -X- _ O

